October 29, 2025OPKO Health, Inc. beats earnings expectations. Reported EPS is $0.03, expectations were $-0.02. Operator: ...

OPKO Health's Q3 earnings top estimates despite lower sales. Cost cuts and product strength boost margins and operating income.

Each year, there are around 200,000 distinct insider transactions reported to SEC via Form 4 filings. While the term “insider trading” sounds nefarious, there are just a handful of cases deemed ...

OPK and PFE received FDA approval for Ngenla in June. This enables OPK to receive royalties going forward. OPK has continued to lose money due to its lab business. The business had sales fall off ...

OPKO Health has improved its financial position by selling most of BioReference, reducing cash burn, and strengthening its balance sheet. Ngenla's profit share with Pfizer has underperformed ...